PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18715868-5 2008 Co-expression of an aggregate prone protein such as expanded polyglutamine in IBMPFD mutant cells results in an increase in aggregated protein that localizes to small inclusions instead of a single perinuclear aggresome. polyglutamine 61-74 valosin containing protein Homo sapiens 78-84 18798739-11 2008 The control of VCP expression is also proposed to be a potential therapeutic target in ex-polyQ-induced neurodegenerative diseases [12]. polyglutamine 90-95 valosin containing protein Homo sapiens 15-18 25231079-3 2014 We found that the aggregates formed by polyQ-expanded Atx3 sequester its interacting partners, such as P97/VCP and ubiquitin conjugates, into the protein inclusions through specific interactions both in vitro and in cells. polyglutamine 39-44 valosin containing protein Homo sapiens 103-110 18715868-9 2008 Expression of HDAC6 improves aggresome formation and protects IBMPFD mutant cells from polyglutamine-induced cell death. polyglutamine 87-100 valosin containing protein Homo sapiens 62-68 18208395-7 2008 VCP was also involved in the clearance of pre-formed polyglutamine aggregates. polyglutamine 53-66 valosin containing protein Homo sapiens 0-3 18208395-8 2008 Paradoxically, VCP knockdown also diminished polyglutamine aggregate formation. polyglutamine 45-58 valosin containing protein Homo sapiens 15-18 12938736-6 2003 In this review, we summarize recent findings on such ambiguous effects of molecular chaperones on polyglutamine diseases, and discuss possible mechanisms by which molecular chaperones, especially VCP, are involved in the pathogenesis. polyglutamine 98-111 valosin containing protein Homo sapiens 196-199 17584300-8 2007 Paradoxically, VCP knockdown also diminished polyglutamine aggregate formation. polyglutamine 45-58 valosin containing protein Homo sapiens 15-18 16822850-7 2006 AT3 binds VCP/p97, a key protein responsible for extracting ERAD substrates from the ER; binding is modulated by the size of the polyglutamine tract, and mutating a sequence adjacent to the polyglutamine tract inhibits the AT3-VCP interaction and AT3-dependent accumulation of CD3delta. polyglutamine 129-142 valosin containing protein Homo sapiens 10-13 16822850-7 2006 AT3 binds VCP/p97, a key protein responsible for extracting ERAD substrates from the ER; binding is modulated by the size of the polyglutamine tract, and mutating a sequence adjacent to the polyglutamine tract inhibits the AT3-VCP interaction and AT3-dependent accumulation of CD3delta. polyglutamine 129-142 valosin containing protein Homo sapiens 14-17 16822850-7 2006 AT3 binds VCP/p97, a key protein responsible for extracting ERAD substrates from the ER; binding is modulated by the size of the polyglutamine tract, and mutating a sequence adjacent to the polyglutamine tract inhibits the AT3-VCP interaction and AT3-dependent accumulation of CD3delta. polyglutamine 129-142 valosin containing protein Homo sapiens 227-230 16822850-7 2006 AT3 binds VCP/p97, a key protein responsible for extracting ERAD substrates from the ER; binding is modulated by the size of the polyglutamine tract, and mutating a sequence adjacent to the polyglutamine tract inhibits the AT3-VCP interaction and AT3-dependent accumulation of CD3delta. polyglutamine 190-203 valosin containing protein Homo sapiens 10-13 16822850-7 2006 AT3 binds VCP/p97, a key protein responsible for extracting ERAD substrates from the ER; binding is modulated by the size of the polyglutamine tract, and mutating a sequence adjacent to the polyglutamine tract inhibits the AT3-VCP interaction and AT3-dependent accumulation of CD3delta. polyglutamine 190-203 valosin containing protein Homo sapiens 14-17 16822850-7 2006 AT3 binds VCP/p97, a key protein responsible for extracting ERAD substrates from the ER; binding is modulated by the size of the polyglutamine tract, and mutating a sequence adjacent to the polyglutamine tract inhibits the AT3-VCP interaction and AT3-dependent accumulation of CD3delta. polyglutamine 190-203 valosin containing protein Homo sapiens 227-230 17584300-7 2007 VCP was involved in the clearance of pre-formed polyglutamine aggregates as well. polyglutamine 48-61 valosin containing protein Homo sapiens 0-3 12784666-7 2002 VCP co-localizes not only with polyglutamine aggregates but also other protein aggregates and Lewy bodies. polyglutamine 31-44 valosin containing protein Homo sapiens 0-3 11598795-3 2001 Endogenous VCP co-localized with expanded polyQ (ex-polyQ) aggregates in cultured cells expressing ex-polyQ, with nuclear inclusions in Huntington disease patient brains, and with Lewy bodies in patient samples. polyglutamine 42-47 valosin containing protein Homo sapiens 11-14 11598795-3 2001 Endogenous VCP co-localized with expanded polyQ (ex-polyQ) aggregates in cultured cells expressing ex-polyQ, with nuclear inclusions in Huntington disease patient brains, and with Lewy bodies in patient samples. polyglutamine 52-57 valosin containing protein Homo sapiens 11-14 11598795-3 2001 Endogenous VCP co-localized with expanded polyQ (ex-polyQ) aggregates in cultured cells expressing ex-polyQ, with nuclear inclusions in Huntington disease patient brains, and with Lewy bodies in patient samples. polyglutamine 52-57 valosin containing protein Homo sapiens 11-14